Detailed price information for Castle Biosciences Inc (CSTL-Q) from The Globe and Mail including charting and trades.
Metabolic dysfunction-associated steatotic liver disease (MASLD) is significantly associated with eosinophilic esophagitis ...
Castle Biosciences (NASDAQ:CSTL) reported second-quarter 2026 revenue of $103.5 million, up 20% from the prior-year period, ...
Q2 2026 Earnings Call July 30, 2026 4:30 PM EDTCompany ParticipantsCamilla Zuckero - Vice President of Investor ...
Welcome to Merit Medical Systems' Second Quarter 2026 Earnings Conference Call. [Operator Instructions] Please note that this conference call is being recorded and that the recording will be available ...
A pointed exchange between Justice Amy Coney Barrett and Solicitor General D. John Sauer stood out during Wednesday’s Supreme Court hearing on President Donald Trump’s use of emergency powers to ...
Spoiler alert: The following article contains spoilers from the Chicago Med season 11 premiere. Chicago Med is no stranger to cast exits, and they're losing yet another star in season 11 — Marlyne ...
Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the second quarter ended June 30, 2026.
Delivered Q2 2026 revenue of $103.5 millionQ2 2026 total test reports for our core revenue drivers (DecisionDx®-Melanoma, TissueCypher®) increased 32% over Q2 2025Raising ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results